Scancell Hlds SCLP Moditope Vaccine Technology Platform

  Scancell Hlds (SCLP) - Moditope Vaccine Technology Platform

RNS Number : 0889K
Scancell Holdings Plc
15 August 2012


15 August 2012

                            Scancell Holdings Plc

                                 ('Scancell')

                                      

                   ModitopeÔ vaccine technology platform

                                      

     Stimulation of killer CD4 T cells with potent anti-tumour activity

                                      

                                      



Scancell  Holdings  Plc,  (AIM:SCLP),  the  developer  of  therapeutic  cancer 
vaccines,  today  announcesthedevelopment  of  a  new  platform   technology 
(ModitopeÔ) that  stimulates  the  production  of killer  CD4  T  cells  with 
powerful anti-tumour activity. The Directors believe that this new  discovery 
could have a profound effect on the way that cancer vaccines are developed.



CD4 responses to cancer associated antigens have been notoriously difficult to
generate whether presented as peptides, proteins  or DNA. CD4 cells are  vital 
for effective anti-tumour  immunity. Scancell has  identified and patented  a 
series  of  modified  epitopes  that  overcome  this  limitation.   Scancell's 
ModitopeÔ technology produces killer CD4 T cells that destroy tumours  without 
toxicity



Professor Lindy  Durrant, Joint  CEO  of Scancell  Holdings and  Professor  of 
Cancer Immunotherapy at Nottingham University,  commented: "Not only do  these 
unique epitopes stimulate a CD4 killer T cell response, we have also shown  in 
tests that cancer patients can produce  an immune response to these  epitopes. 
The ModitopeÔ epitopes can  be used to develop  both DNA and peptide  vaccines 
and could become an  important component of many  therapeutic vaccines in  the 
future, both under development at Scancell and other companies"



Prof Peter Stern,  Head of  the Cancer Research  UK, Immunology  Group at  the 
Paterson Institute for Cancer Research, commented: "This novel technology  has 
the potential to transform  the therapeutic cancer  field. It is  increasingly 
recognised that  combining  products and  technologies  will unlock  the  full 
potential of cancer vaccines. The ModitopeÔ technology offers those developing
cancer vaccines, a means to optimise the potency of their immune targets".



David Evans, Chairman of Scancell Holdings, commented: "This highly innovative
discovery opens up  a new approach  to the development  of cancer  vaccines. 
Whilst currently at an early stage, we are aware that the opportunities  could 
be considerable in addition to  Scancell's existing platform technology. As  a 
result, the Board is  actively evaluating its strategic  options for this  new 
technology platform  and will  be  consulting with  key shareholders  in  this 
regard. We  are excited  by the  potential and  are resolute  in our  aim  of 
creating the greatest value for shareholders. The Board will update the market
in due course."





The Directors of the issuer accept responsibility for this announcement.

                                      



                                    -ENDS-











For Further Information:

Dr Richard Goodfellow, Joint CEO   Scancell Holdings Plc + 44 207 653 9850

Professor Lindy Durrant, Joint CEO Scancell Holdings Plc + 44 207 653 9850
Graham Herring/Heather Armstrong   Newgate Threadneedle  + 44 207 653 9850
Ross Andrews / Tom Rowley          Zeus Capital          + 44 161 831 1512
Jon Belliss/Karen Kelly            Xcap Securities Plc   + 44 207 101 7070



















About Scancell



Scancell is developing novel therapeutic vaccines for the treatment of  cancer 
and infectious diseases based on its groundbreaking ImmunoBody® and  Moditope™ 
technology platforms. Scancell's first cancer vaccine SCIB1 is being developed
for the treatment of melanoma and is in Phase 2 clinical trials.



Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a  patient, stimulating an  immune response. Effective  cancer 
vaccines need  to  target dendritic  cells  to  stimulate both  parts  of  the 
cellular  immune  system;  the  helper  cell  system  where  inflammation   is 
stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL  response 
where immune system cells are primed to recognise and kill specific cells.



A limitation of  many cancer vaccines  currently in development  is that  they 
cannot specifically  target  dendritic  cells in  vivo.  Several  groups  have 
demonstrated successful  vaccination  by  growing  dendritic  cells  ex  vivo, 
pulsing  them  with  tumour  antigens  and  re-infusing  them.  However,  this 
procedure is  patient specific,  time consuming  and expensive.  Scancell  has 
developed its breakthrough patent protected ImmunoBody® technology to overcome
these limitations.



An ImmunoBody® is  a human antibody  or fusion protein  engineered to  express 
helper cell and  CTL epitopes  from tumour antigens  over-expressed by  cancer 
cells. Antibodies are ideal vectors for  carrying T cell epitopes from  tumour 
antigens as they  have long  half-lives and can  effectively target  dendritic 
cells via their Fc  receptors, allowing efficient  stimulation of both  helper 
and CTL responses.



The Immunobody® technology can  be adapted to provide  the basis for  treating 
any tumour type and  may also be  of potential utility  in the development  of 
vaccines against hepatitis, HIV and other chronic infectious diseases.



Scancell has also identified and patented  a series of modified epitopes  that 
stimulate the production of killer CD4 that destroy tumours without  toxicity. 
The Directors believe that the Moditope™ platform could have a profound effect
on the way that cancer vaccines are developed.











                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


MSCEAAPSFFEAEFF -0- Aug/15/2012 12:12 GMT
 
Press spacebar to pause and continue. Press esc to stop.